Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101)

被引：9

作者：

Choueiri, Toni K.

Rini, Brian I.

Larkin, James M. G.

Bjarnason, Georg A.

Gravis, Gwenaelle

Gurney, Howard

Lee, Jae-Lyun

Keizman, Daniel

Haanen, John B. A. G.

Tomita, Yoshihiko

Uemura, Hirotsugu

Albiges, Laurence

Schmidinger, Manuela

Atkins, Michael B.

Mariani, Mariangela

Shnaidman, Michael

Di Pietro, Alessandra

Motzer, Robert J.

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Brigham & Womens Hosp, Boston, MA USA

[3] Cleveland Clin, Taussig Canc Insitute, Cleveland, OH USA

[4] Royal Marsden NHS Fdn Trust, London, England

[5] Sunnybrook Res Inst, Toronto, ON, Canada

[6] Inst Paoli Calmettes, Marseille, France

[7] Macquarie Univ Hosp, Sydney, NSW, Australia

[8] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[9] Meir Med Ctr, Kefar Sava, Israel

[10] Netherlands Canc Inst, Amsterdam, Netherlands

[11] Niigata Univ, Dev Urol, Grad Sch Med & Dent Sci, Niigata, Japan

[12] Kindai Univ Sakai Hosp, Osaka, Japan

[13] Gustave Roussy Canc Campus, Villejuif, France

[14] Univ Paris Sud, Villejuif, France

[15] Med Univ Vienna, Vienna, Austria

[16] Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC USA

[17] Pfizer Inc, Milan, Italy

[18] Pfizer Inc, New York, NY USA

[19] Pfizer Inc, Lombardia, Italy

[20] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.TPS4594

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4594

引用

页数：5